AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.

AbbVie Inc. has successfully priced a multi-tranche offering of Senior Notes totaling $15 billion on February 22, 2024. The offering includes various maturities: $2.25 billion due 2027, $2.5 billion due 2029, $2 billion due 2031, $3 billion due 2034, $750 million due 2044, $3 billion due 2054, and $1.5 billion due 2064, with interest rates ranging from 4.800% to 5.500%. The trade date was February 22, 2024, with a settlement date set for February 26, 2024. The notes received ratings of A3 (Stable) from Moody's and A- (Stable) from Standard & Poor's. The offering was registered with the SEC and managed by a syndicate of banks, including Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup, among others. The notes are expected to be delivered on a T+2 basis, with interest payments commencing on September 15, 2024. This strategic move by AbbVie aims to diversify its funding sources and extend its debt maturity profile.